113,326 Shares in Omeros Co. (NASDAQ:OMER) Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Omeros Co. (NASDAQ:OMER) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 113,326 shares of the biopharmaceutical company’s stock, valued at approximately $1,120,000.

A number of other institutional investors have also recently added to or reduced their stakes in OMER. Truvestments Capital LLC grew its stake in Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 1,669 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 7,016 shares during the last quarter. MML Investors Services LLC grew its stake in Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 3,000 shares during the last quarter. US Bancorp DE bought a new position in Omeros during the 4th quarter worth $81,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Omeros during the 4th quarter worth $121,000. 48.79% of the stock is currently owned by institutional investors.

Omeros Stock Up 1.3 %

Shares of Omeros stock opened at $9.10 on Friday. The firm has a market cap of $527.35 million, a price-to-earnings ratio of -3.94 and a beta of 2.03. The business has a fifty day simple moving average of $8.70 and a 200-day simple moving average of $7.28. Omeros Co. has a fifty-two week low of $2.61 and a fifty-two week high of $13.60.

Wall Street Analyst Weigh In

OMER has been the subject of several recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Friday, January 17th. StockNews.com cut Omeros from a “hold” rating to a “sell” rating in a research note on Friday. Finally, D. Boral Capital reissued a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Thursday, February 20th. One analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Omeros has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.